Volume : 09, Issue : 05, May – 2022
Title:
18.IMPACT OF DIABETIES MELLITUS ON PULMONARY FUNCTION TEST IN COPD PATIENTS
Authors :
Raksha, Pranjul Jain, Ravindra, Gomti Patel, Mrs. Sunayana Kesharwani*
Abstract :
COPD is a multisystemic inflammatory illness that affects more than only the lungs. The link between reduced lung function and diabetes has been investigated for many years, suggesting that the lung could be a target organ in diabetes. Diabetes mellitus (DM) pulmonary effects are poorly understood. Some publications have observed normal pulmonary functions in diabetes individuals and even concluded that spirometry is not required. In other investigations, people with DM had altered respiratory parameters. Furthermore, the duration of diabetes and glycemic control have different effects on pulmonary function. The present review focus on impact of diabeties mellitus on pulmonary function test in COPD patients.
Key Words:Diabeties Mellitus, Pulmonary function, COPD Patients
Cite This Article:
Please cite this article in press Sunayana Kesharwani et al,Impact Of Diabeties Mellitus On Pulmonary Function Test In Copd Patients.,Indo Am. J. P. Sci, 2022; 09(5).,
Number of Downloads : 10
References:
1. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN: Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 2010; 24: 600– 608.
2. Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962–969.
3. Danaei G, Finucane MM, Lu Y, et al: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31–40.
4. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W: Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One 2012; 7:e43892.
5. Song Y, Klevak A, Manson JE, Buring JE, Liu S: Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women’s Health Study. Diabetes Res Clin Pract 2010; 90: 365–371.
6. Lawlor DA, Ebrahim S, Smith GD: Associations of measures of lung function with insulin resistance and type 2 diabetes: findings from the British Women’s Heart and Health Study. Diabetologia 2004; 47: 195–203.
7. Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, Soler X, Silverman EK, Crapo J, Hokanson JE; COPDGene Investigators: Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. Diabetes Care 2014; 37: 389–395.
8. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067–2072.
9. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH: Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 2004; 64: 99–106.
10. Burgel PR, Escamilla R, Perez T, et al: Impact of comorbidities on COPD-specific healthrelated quality of life. Respir Med 2013; 107: 233–241.
11. Habib G, Dar-Esaif Y, Bishara H, Artul S, Badarny S, Chernin M, Jabbour A: The impact of corticosteroid treatment on hemoglobin A1C levels among patients with type-2 diabetes with chronic obstructive pulmonary disease exacerbation. Respir Med 2014; 108: 1641–1646.
12. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001; 32: 2426–2432.
13. Moretti M, Cilione C, Tampieri A, Fracchia C, Marchioni A, Nava S: Incidence and causes of non-invasive mechanical ventilation failure after initial success. Thorax 2000; 55: 819–825.
14. Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley PM: Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 2009; 64: 857–862.
15. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B: Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132: 1748–1755.
16. Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA, Hansen JM: Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 2014; 306:L43–L49.
17. Jones PW, Nadeau G, Small M, Adamek L: Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Respir Med 2014; 108: 129–135
18. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010; 80: 112–119
19. Heianza Y, Arase Y, Tsuji H, Saito K, Amakawa K, Hsieh SD, Kodama S, Shimano H, Yamada N, Hara S, Sone H: Low lung function and risk of type 2 diabetes in Japanese men: the Toranomon Hospital Health Management Center Study 9 (TOPICS 9). Mayo Clin Proc 2012; 87: 853–861.
20. Ford ES, Mannino DM, National H: Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study. Diabetes Care 2004; 27: 2966–2970.
21. Wannamethee SG, Shaper AG, Rumley A, Sattar N, Whincup PH, Thomas MC, Lowe GD: Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation. Diabetes Care 2010; 33: 1990– 1996.
22. Park SK, Larson JL: The relationship between physical activity and metabolic syndrome in people with chronic obstructive pulmonary disease. J Cardiovasc Nurs 2014; 29: 499–507.
23. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384–2389.
24. Takenaka S, Kawayama T, Imaoka H, Sakazaki Y, Oda H, Kaku Y, Matsuoka M, Okamoto M, Kato S, Yamada K, Hoshino T: The progression of comorbidity in IL-18 transgenic chronic obstructive pulmonary disease mice model. BiochemBiophys Res Commun 2014; 445: 597–601.
25. Groenewegen KH, Schols AM, Wouters EF: Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467.
26. Suissa S, Kezouh A, Ernst P: Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001–1006.
27. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN: Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011; 96: 1789–1796.
28. O’Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, Carlsson LG, Sin DD: Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med 2012; 106: 1487– 1493.
29. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, et al: Short-term vs. conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309: 2223–2231.
30. Anton E: How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med 2013; 7: 25– 32.